News | June 21, 2026
Evonik sells Hanau pharma assets to ProChem in strategic portfolio shift
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
The validation confirms the submission is complete, clearing the way for the EMA’s centralized review process to formally evaluate the therapy
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
The collaboration introduces a flexible, end-to-end CDx framework designed to adapt to shifting regulatory environments
The approval marks a major milestone in the global fight against antimicrobial resistance
The conference highlighted research suggesting that deuterium levels may influence key biological processes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
